GTHP (Guided Therapeutics) Long-Term Debt: $0.19 Mil (As of Mar. 2026)


GTHP Guided Therapeutics Inc GTHP
18 GF Score
Price $0.28
! 4 Warning Signs
View Full Analysis

What is Guided Therapeutics Long-Term Debt?

Guided Therapeutics GTHP +14.29% 18 Long-Term Debt is $0.19 Mil as of Mar. 2026. GuruFocus rates GTHP with a GF Score™ of 18/100. The stock has 4 warning signs investors should review.

Guided Therapeutics's Long-Term Debt for the quarter that ended in Mar. 2026 was $0.19 Mil.

Guided Therapeutics's quarterly Long-Term Debt declined from Sep. 2025 ($0.08 Mil) to Dec. 2025 ($0.04 Mil) but then increased from Dec. 2025 ($0.04 Mil) to Mar. 2026 ($0.19 Mil).

Guided Therapeutics's annual Long-Term Debt declined from Dec. 2023 ($0.51 Mil) to Dec. 2024 ($0.06 Mil) and declined from Dec. 2024 ($0.06 Mil) to Dec. 2025 ($0.04 Mil).

Guided Therapeutics  (OTCPK:GTHP) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Guided Therapeutics Long-Term Debt Related Terms

Guided Therapeutics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Guided Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guided Therapeutics Long-Term Debt Chart

Guided Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.43 1.13 0.51 0.06 0.04

Guided Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.04 0.08 0.04 0.19
GTHP
18GF Score
Guided Therapeutics Inc GTHP
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.19 Mil mean?
Guided Therapeutics (GTHP) has a Long-Term Debt of $0.19 Mil as of Mar. 2026.
Is Guided Therapeutics' Long-Term Debt too high?
Guided Therapeutics' current Long-Term Debt is $0.19 Mil. Overall, Guided Therapeutics has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Guided Therapeutics' Long-Term Debt compare to CTSO and IRIX?
Guided Therapeutics' Long-Term Debt of $0.19 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Devices & Instruments company?
A good Long-Term Debt depends on the Medical Devices & Instruments industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Guided Therapeutics's current Long-Term Debt is $0.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guided Therapeutics stock overvalued right now?
Guided Therapeutics (GTHP) has a current Long-Term Debt of $0.19 Mil. The current Long-Term Debt is $0.19 Mil. Guided Therapeutics' overall GF Score™ is 18/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Guided Therapeutics (GTHP), the current Long-Term Debt is $0.19 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Guided Therapeutics Business Description

Address 5835 Peachtree Corners East, Suite B, Peachtree Corners, GA, USA, 30092
Guided Therapeutics Inc is a medical technology company. It is engaged in developing medical devices that have the potential to improve healthcare. Its primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device and the extension of its cancer detection technology into other cancers, including esophageal. The company generates revenue from the sale of medical devices.
18GF Score

Get the complete analysis for GTHP

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.28
Price